From high BMI to the ‘GLP-1 look’: how weight-loss jabs are changing the face of beauty

The phrase refers to the hollowed cheeks, temples, or under-eye area that can follow rapid weight loss; it is an aesthetic description, not a diagnosis. That distinction matters because a social label can quickly sound medical even when it is really describing how people read faces in public.

At a European obesity conference, paediatric endocrinologist Michael Yafi used art history to make the point. Fuller bodies once signaled wealth, status, and wellbeing in much Western art, he said, and he speculated that a thinner, more drawn look could become a recurring visual type as these medicines spread.

Rosalind Gill, a scholar of media and culture, offered the harder cultural question: whether a market hungry for new looks could turn a side effect people often dislike into something aspirational. That is a concern about beauty norms and consumer pressure, not evidence that one new ideal has already taken hold.

Art historian Bendor Grosvenor pushed back on using the Mona Lisa as shorthand, warning against treating a portrait as medical evidence. The useful tension is between a real shift in the visibility of weight-loss drugs and the much less certain claim that any one face, body, or historical painting tells us what beauty should mean.

Read the full story at The Guardian ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.